FOXK1 and ovarian carcinoma: Moreover, Aurora-A appears to exert a regulatory role through direct binding and phosphorylation of the transcription factor SOX8 to activate the SOX8/FOXK1 signaling axis, highlighting this pathway as a novel potential therapeutic target for chemoresistant ovarian cancer.